Our latest articles
Sanofi’s oncology hopes crumble
The discontinuation of amcenestrant piles more pressure on the group’s chief executive, Paul Hudson.
Blueprint for disappointment
Ayvakit hits in its pivotal indolent systemic mastocytosis trial, but a dwindling effect size reignites commercial concerns.
GSK raises more questions about synthetic lethality
Six months on from axing Epizyme’s PRMT-targeting projects GSK says no to Ideaya’s Mat2A work.
Viridian takes on Horizon
Early data in thyroid eye disease impress, but unanswered questions include the size of the market.
Canakinumab’s cancer career ends with a whimper
Novartis's latest failure, in adjuvant lung cancer, heaps more doubt on a rival approach from Cantargia.
Zantac burns big pharma
As Zantac litigation risk wipes $43bn off public company valuations are investors right to be worried?
Trad device start-ups catch the cash
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.
Cytokine players keep the faith
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
The Sting is dead; long live the Sting
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.
Pfizer bets $5.4bn against gene therapies in sickle cell
Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.
